In summary, Exo-PD-L1, instead of sPD-L1, was higher in NSCLC patients with advanced TNM tumor stage, larger tumor size (> 2.5 cm), positive lymph node status and distant metastasis. This evidence concerns the gene SPDL1 and neoplasm.